year
fi
rst
identifi
ed
case
middl
east
respiratori
syndrom
coronaviru
merscov
infect
specifi
c
treatment
proven
eff
ectiv
exist
peopl
infect
viru
countri
report
includ
relat
death
result
larg
hospit
outbreak
king
abdulaziz
medic
citi
riyadh
saudi
arabia
august
septemb
saudi
arabian
ministri
nation
guard
health
aff
air
organis
day
research
initi
workshop
sept
make
recommend
therapeut
panel
nontherapeut
panel
research
merscov
recognis
crucial
role
scientifi
c
polit
partnership
ministri
nation
guard
health
aff
air
invit
key
repres
region
intern
health
agenc
expert
basic
translat
scienc
diagnost
therapeut
epidemiolog
infect
prevent
control
clinic
research
public
health
sever
pharmaceut
compani
present
statu
merscov
treatment
candid
develop
primari
object
exchang
knowledg
prioritis
potenti
treatment
assess
clinic
trial
saudi
arabia
promis
treatment
discuss
meet
includ
immunotherapi
merscovspecifi
c
antibodi
convalesc
plasma
monoclon
polyclon
antibodi
addit
sever
new
repurpos
small
molecul
drug
candid
need
assess
phase
clinic
trial
demonstr
although
much
fundament
preclin
studi
done
assess
promis
drug
appropri
anim
model
optimum
next
step
clinic
trial
start
preclin
studi
begin
immedi
clinic
studi
begin
soon
view
episod
natur
middl
east
respiratori
syndrom
coronaviru
merscov
infect
human
be
gener
low
number
case
hospit
healthcar
system
intern
collabor
among
scientist
clinician
hospit
extrahospit
health
sector
regul
funder
key
effi
cient
eff
ectiv
implement
clinic
trial
effi
cient
stepwis
approach
gener
scientifi
calli
valid
clinic
research
drive
inform
eventu
incorpor
new
treatment
clinic
practic
relev
parti
continu
assess
progress
includ
multisector
followup
meet
incorpor
advanc
data
better
inform
care
patient
merscov
standardis
case
report
form
develop
accommod
observ
studi
clinic
trial
tier
data
collect
requir
refl
ect
vari
capac
research
across
diff
erent
environ
standard
defi
nition
variabl
allow
data
combin
across
multipl
studi
trial
form
help
creat
integr
databas
includ
epidemiolog
microbiolog
immunolog
clinic
data
specimen
repositori
storag
bank
inform
subsequ
merscov
scientifi
c
inquiri
understand
risk
associ
develop
new
treatment
research
use
portfolio
approach
assess
multipl
complementari
approach
prioritis
approach
advanc
scientifi
c
develop
process
fi
rst
assess
therapeut
research
infrastructur
consid
adapt
clinic
trial
design
allow
either
effi
cient
sequenti
parallel
assess
treatment
comparison
concurr
control
groupid
take
form
allocationconc
randomis
blind
intervent
clinic
trial
outcom
endpoint
clinic
trial
realist
although
demonstr
reduct
mortal
ideal
goal
treatmentbas
clinic
trial
abil
validli
show
mortal
reduct
hamper
likelihood
absolut
mortal
reduct
greater
histor
unlik
mani
intervent
especi
use
infect
caus
sever
ill
organ
dysfunct
like
infeas
studi
enrol
thousand
patient
necessari
show
less
absolut
reduct
mortal
therefor
although
measur
mortal
essenti
trial
consid
import
endpoint
includ
biolog
marker
eff
ect
eg
viral
load
biolog
sampl
especi
earli
phase
clinic
assess
safeti
antimerscov
effi
caci
appropri
anim
model
present
none
treatment
candid
suffi
cient
clinic
data
support
use
clinic
care
knowledg
base
evolv
dynam
new
evid
continu
reassess
